Clinical Trial Update: Neoadjuvant Immunotherapy for Patients With High-risk Eye Melanoma [Phase 1]

View source ↗

Summary

Phase 1 neoadjuvant immunotherapy trial for high-risk uveal melanoma has been updated. The study is currently not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Uveal Melanoma

Snippet

Sponsor: Inge Marie Svane | Conditions: Uveal Melanoma | Phase 1 | Status: NOT_YET_RECRUITING